Repositive Expands Global Cancer Model Network with CRO from Finland

Repositive has expanded its global network of contract research organization (CRO) partners with the addition of Pharmatest, a CRO providing clinically predictive preclinical efficacy services for oncology and skeletal diseases. Pharmatest brings to the partnership more than 20 years of experience in disease modelling, enabling Repositive to further grow its global reach to serve more biopharmaceutical companies in their quest for the right preclinical cancer models to accelerate oncology drug development programs.

"At Repositive, we are committed to establishing new partnerships with specialist CROs to further enhance and strengthen our world-class offering of preclinical cancer models to biopharmaceutical researchers worldwide," said Fiona Nielsen, CEO of Repositive. "Our collaboration with Pharmatest will enable us to do just that. By adding new models to the Repositive Cancer Models Platform, we will continue to support researchers in their preclinical work, providing them with a wider selection of models to choose from, thereby facilitating improved accuracy during the drug discovery process."

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!

At present, the Repositive Cancer Models Platform displays curated and standardized metadata from over 8,000 preclinical cancer models. Biopharmaceutical researchers can browse the available models with the option of filtering content by primary site, model type and subtype, gene mutation, variant, treatment, and treatment response. In vivo oncology researchers and in-house bioinformatics teams can rely on the platform for automated processing, organization and streamlining of cancer model inventories, while the system’s easy-to-access interface allows complex modelling queries to be effortlessly performed.

"We chose to partner with Repositive because of their ground-breaking, compelling platform, which helps to connect key players in the preclinical cancer research field," said Dr Jukka Rissanen, CEO of Pharmatest. "At Pharmatest, we have unique expertise in the field of bone metastases that we want to be able to share as widely as possible and collaborating with Repositive seems like a great way to do this."

Join the Discussion